Annual EBITDA
$6.93 B
-$1.63 B-19.03%
March 31, 2024
Summary
- As of February 7, 2025, TAK annual EBITDA is $6.93 billion, with the most recent change of -$1.63 billion (-19.03%) on March 31, 2024.
- During the last 3 years, TAK annual EBITDA has fallen by -$3.03 billion (-30.44%).
- TAK annual EBITDA is now -30.44% below its all-time high of $9.97 billion, reached on March 31, 2021.
Performance
TAK EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
$1.61 B
-$954.22 M-37.27%
December 1, 2024
Summary
- As of February 7, 2025, TAK quarterly EBITDA is $1.61 billion, with the most recent change of -$954.22 million (-37.27%) on December 1, 2024.
- Over the past year, TAK quarterly EBITDA has dropped by -$954.22 million (-37.27%).
- TAK quarterly EBITDA is now -59.77% below its all-time high of $3.99 billion, reached on June 30, 2021.
Performance
TAK Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
$7.24 B
-$973.83 M-11.86%
December 1, 2024
Summary
- As of February 7, 2025, TAK TTM EBITDA is $7.24 billion, with the most recent change of -$973.83 million (-11.86%) on December 1, 2024.
- Over the past year, TAK TTM EBITDA has dropped by -$973.83 million (-11.86%).
- TAK TTM EBITDA is now -36.10% below its all-time high of $11.33 billion, reached on September 30, 2021.
Performance
TAK TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
TAK EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -19.0% | -37.3% | -11.9% |
| 3 y3 years | -30.4% | +6.3% | -19.7% |
| 5 y5 years | +81.5% | -25.3% | -27.4% |
TAK EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -30.4% | at low | -43.6% | +176.8% | -32.2% | +2.6% |
| 5 y | 5-year | -30.4% | +81.5% | -59.8% | +223.8% | -36.1% | +13.8% |
| alltime | all time | -30.4% | +411.0% | -59.8% | +177.4% | -36.1% | +1028.6% |
Takeda Pharmaceutical Company Limited EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | - | $1.61 B(-37.3%) | $7.24 B(-11.9%) |
| Sep 2024 | - | $2.56 B(+2.7%) | $8.21 B(+16.4%) |
| Jun 2024 | - | $2.49 B(+329.6%) | $7.05 B(-2.4%) |
| Mar 2024 | $6.93 B(-19.0%) | $580.08 M(-77.5%) | $7.23 B(-11.4%) |
| Dec 2023 | - | $2.58 B(+84.2%) | $8.16 B(-0.0%) |
| Sep 2023 | - | $1.40 B(-47.5%) | $8.16 B(-7.6%) |
| Jun 2023 | - | $2.67 B(+76.6%) | $8.83 B(-2.0%) |
| Mar 2023 | $8.56 B(-4.6%) | $1.51 B(-41.5%) | $9.01 B(+10.4%) |
| Dec 2022 | - | $2.58 B(+24.6%) | $8.17 B(+3.0%) |
| Sep 2022 | - | $2.07 B(-27.3%) | $7.93 B(-1.6%) |
| Jun 2022 | - | $2.85 B(+329.3%) | $8.05 B(-12.4%) |
| Mar 2022 | $8.98 B(-9.9%) | $663.84 M(-71.6%) | $9.19 B(-13.9%) |
| Dec 2021 | - | $2.34 B(+6.6%) | $10.68 B(-5.7%) |
| Sep 2021 | - | $2.20 B(-45.0%) | $11.33 B(+3.0%) |
| Jun 2021 | - | $3.99 B(+85.7%) | $11.00 B(+10.3%) |
| Mar 2021 | $9.97 B(+61.2%) | $2.15 B(-28.1%) | $9.97 B(+19.9%) |
| Dec 2020 | - | $2.99 B(+60.2%) | $8.31 B(+14.1%) |
| Sep 2020 | - | $1.87 B(-37.0%) | $7.29 B(-2.1%) |
| Jun 2020 | - | $2.96 B(+497.1%) | $7.44 B(+17.0%) |
| Mar 2020 | $6.18 B(+61.8%) | $496.04 M(-74.7%) | $6.36 B(-0.4%) |
| Dec 2019 | - | $1.96 B(-3.0%) | $6.38 B(+18.6%) |
| Sep 2019 | - | $2.02 B(+7.6%) | $5.38 B(+22.5%) |
| Jun 2019 | - | $1.88 B(+261.5%) | $4.40 B(+13.7%) |
| Mar 2019 | $3.82 B(+3.4%) | $519.95 M(-45.8%) | $3.87 B(+31.5%) |
| Dec 2018 | - | $959.76 M(-7.3%) | $2.94 B(-0.8%) |
| Sep 2018 | - | $1.04 B(-23.3%) | $2.96 B(+8.8%) |
| Jun 2018 | - | $1.35 B(-432.7%) | $2.72 B(-25.6%) |
| Mar 2018 | $3.69 B(+24.0%) | -$405.73 M(-141.3%) | $3.66 B(-5.8%) |
| Dec 2017 | - | $982.45 M(+23.5%) | $3.89 B(+1.5%) |
| Sep 2017 | - | $795.78 M(-65.2%) | $3.83 B(+2.0%) |
| Jun 2017 | - | $2.29 B(-1376.8%) | $3.75 B(+13.5%) |
| Mar 2017 | $2.98 B(+2.2%) | -$179.14 M(-119.4%) | $3.31 B(-9.5%) |
| Dec 2016 | - | $924.59 M(+28.6%) | $3.65 B(+0.3%) |
| Sep 2016 | - | $718.97 M(-61.0%) | $3.64 B(-5.9%) |
| Jun 2016 | - | $1.84 B(+999.9%) | $3.87 B(+34.3%) |
| Mar 2016 | $2.92 B | $167.39 M(-81.7%) | $2.88 B(+349.7%) |
| Dec 2015 | - | $915.45 M(-3.5%) | $641.37 M(-47.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2015 | - | $948.47 M(+11.2%) | $1.21 B(-7.8%) |
| Jun 2015 | - | $853.05 M(-141.1%) | $1.32 B(-17.8%) |
| Mar 2015 | $1.36 B(-66.5%) | -$2.08 B(-239.5%) | $1.60 B(-61.4%) |
| Dec 2014 | - | $1.49 B(+41.5%) | $4.15 B(+4.3%) |
| Sep 2014 | - | $1.05 B(-7.7%) | $3.98 B(-3.4%) |
| Jun 2014 | - | $1.14 B(+140.7%) | $4.12 B(+1.4%) |
| Mar 2014 | $4.05 B(-16.5%) | $473.05 M(-64.0%) | $4.06 B(+18.5%) |
| Dec 2013 | - | $1.32 B(+10.5%) | $3.43 B(+33.9%) |
| Sep 2013 | - | $1.19 B(+9.9%) | $2.56 B(+23.4%) |
| Jun 2013 | - | $1.08 B(-778.0%) | $2.07 B(+6.6%) |
| Mar 2013 | $4.85 B(-5.4%) | -$159.71 M(-135.7%) | $1.95 B(+12.3%) |
| Dec 2012 | - | $447.83 M(-36.4%) | $1.73 B(-22.5%) |
| Sep 2012 | - | $703.99 M(-26.2%) | $2.24 B(-17.1%) |
| Jun 2012 | - | $954.50 M(-356.2%) | $2.70 B(-15.9%) |
| Mar 2012 | $5.13 B(-8.0%) | -$372.52 M(-139.1%) | $3.21 B(-26.8%) |
| Dec 2011 | - | $952.55 M(-18.3%) | $4.39 B(-13.7%) |
| Sep 2011 | - | $1.17 B(-20.4%) | $5.08 B(-9.7%) |
| Jun 2011 | - | $1.47 B(+82.5%) | $5.63 B(+0.9%) |
| Mar 2011 | $5.57 B(-2.9%) | $802.86 M(-51.3%) | $5.58 B(-0.1%) |
| Dec 2010 | - | $1.65 B(-3.7%) | $5.59 B(+1.1%) |
| Sep 2010 | - | $1.71 B(+21.2%) | $5.53 B(+2.5%) |
| Jun 2010 | - | $1.41 B(+74.3%) | $5.39 B(-5.5%) |
| Mar 2010 | $5.73 B(+10.0%) | $811.00 M(-49.0%) | $5.70 B(-4.7%) |
| Dec 2009 | - | $1.59 B(+0.7%) | $5.99 B(-5.0%) |
| Sep 2009 | - | $1.58 B(-8.6%) | $6.30 B(+9.7%) |
| Jun 2009 | - | $1.73 B(+57.9%) | $5.75 B(+43.0%) |
| Mar 2009 | $5.21 B(-2.5%) | $1.09 B(-42.6%) | $4.02 B(+37.4%) |
| Dec 2008 | - | $1.91 B(+87.0%) | $2.92 B(+187.0%) |
| Sep 2008 | - | $1.02 B | $1.02 B |
| Mar 2008 | $5.34 B(-4.6%) | - | - |
| Mar 2007 | $5.60 B(+15.7%) | - | - |
| Mar 2006 | $4.84 B(+9.8%) | - | - |
| Mar 2005 | $4.40 B(+4.6%) | - | - |
| Mar 2004 | $4.21 B(+10.9%) | - | - |
| Mar 2003 | $3.80 B(+17.8%) | - | - |
| Mar 2002 | $3.22 B(+19.5%) | - | - |
| Mar 2001 | $2.70 B(+26.1%) | - | - |
| Mar 2000 | $2.14 B | - | - |
FAQ
- What is Takeda Pharmaceutical Company Limited annual EBITDA?
- What is the all time high annual EBITDA for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited annual EBITDA year-on-year change?
- What is Takeda Pharmaceutical Company Limited quarterly EBITDA?
- What is the all time high quarterly EBITDA for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited quarterly EBITDA year-on-year change?
- What is Takeda Pharmaceutical Company Limited TTM EBITDA?
- What is the all time high TTM EBITDA for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited TTM EBITDA year-on-year change?
What is Takeda Pharmaceutical Company Limited annual EBITDA?
The current annual EBITDA of TAK is $6.93 B
What is the all time high annual EBITDA for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high annual EBITDA is $9.97 B
What is Takeda Pharmaceutical Company Limited annual EBITDA year-on-year change?
Over the past year, TAK annual EBITDA has changed by -$1.63 B (-19.03%)
What is Takeda Pharmaceutical Company Limited quarterly EBITDA?
The current quarterly EBITDA of TAK is $1.61 B
What is the all time high quarterly EBITDA for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high quarterly EBITDA is $3.99 B
What is Takeda Pharmaceutical Company Limited quarterly EBITDA year-on-year change?
Over the past year, TAK quarterly EBITDA has changed by -$954.22 M (-37.27%)
What is Takeda Pharmaceutical Company Limited TTM EBITDA?
The current TTM EBITDA of TAK is $7.24 B
What is the all time high TTM EBITDA for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high TTM EBITDA is $11.33 B
What is Takeda Pharmaceutical Company Limited TTM EBITDA year-on-year change?
Over the past year, TAK TTM EBITDA has changed by -$973.83 M (-11.86%)